institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 1 day ago • loading... • Updated 1 day ago

A New Standard in First-Line Therapy for HER2-Positive Breast Cancer?

Summary by MedPage Today

(MedPage Today) -- In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab (Perjeta) improved progression-free...

1 Articles

1 Articles

All

Left

Center

1

Right

A New Standard in First-Line Therapy for HER2-Positive Breast Cancer?

(MedPage Today) -- In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab (Perjeta) improved progression-free...

1 day ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated1 day agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MedPage Today broke the news in New York, United States 1 day ago on Friday, June 13, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics